Coursera's stock rallies more than 14% after company's narrower quarterly loss, raised guidance
Shares of Coursera Inc. (COUR) rallied more than 14% in the extended session Thursday after the open online course provider reported a narrower-than-expected third-quarter loss and raised its revenue guidance for the year. Coursera lost $32.1 million, or 21 cents a share, in the quarter, compared with a loss of $36 million, or 25 cents a share, in the year-ago period. Revenue rose 21% to $165.5 million, the company said. FactSet consensus called for a GAAP loss of 26 cents a share on sales of $158 million. "We accelerated our AI-powered translation initiative to deliver over 4,000 courses in seven languages, broadening access to the world's best educators and trusted brands for the millions of new learners coming to our platform," Chief Executive Jeff Maggioncalda said in a statement. Coursera also raised its revenue outlook, calling for fourth-quarter revenue between $161 million and $165 million and 2023 revenue between $628 million and $632 million.
-Claudia Assis
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-26-23 1635ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks